Key Points
- STERIS director Mohsen Sohi sold 4,058 shares at an average price of $235.78, generating approximately $956,795. After the sale, his ownership fell 14.31% to 24,305 shares.
- STERIS reported quarterly EPS of $2.59, beating estimates by $0.10, while revenue reached $1.49 billion and rose 7.3% year over year. The company issued fiscal 2027 EPS guidance of $11.00–$11.30.
- The company increased its quarterly dividend from $0.63 to $0.69 per share, equivalent to an annualized $2.76 dividend and a 1.2% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $271.33.
STERIS plc (NYSE:STE - Get Free Report) Director Mohsen Sohi sold 4,058 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the transaction, the director owned 24,305 shares of the company's stock, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
STERIS Price Performance
NYSE:STE opened at $236.25 on Thursday. The firm's fifty day moving average is $216.51 and its two-hundred day moving average is $224.71. The firm has a market cap of $23.03 billion, a price-to-earnings ratio of 28.88 and a beta of 0.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.35 and a current ratio of 1.91. STERIS plc has a one year low of $195.14 and a one year high of $269.44.
STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share for the quarter, beating analysts' consensus estimates of $2.49 by $0.10. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%.The company's revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the business posted $2.34 EPS. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Research analysts expect that STERIS plc will post 11.09 EPS for the current year.
STERIS Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 1.2%. This is a positive change from STERIS's previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Friday, September 4th. STERIS's dividend payout ratio is 30.81%.
Institutional Trading of STERIS
Several institutional investors have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new position in shares of STERIS during the 1st quarter worth about $25,000. Elevation Wealth Partners LLC lifted its stake in STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 113 shares in the last quarter. Activest Wealth Management boosted its holdings in STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider's stock worth $28,000 after buying an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in STERIS in the 4th quarter worth about $28,000. Finally, Geneos Wealth Management Inc. boosted its holdings in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after buying an additional 104 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have issued reports on STE shares. Wall Street Zen raised STERIS from a "hold" rating to a "buy" rating in a report on Sunday. Piper Sandler reaffirmed an "overweight" rating and set a $275.00 price objective (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. KeyCorp cut their target price on shares of STERIS from $291.00 to $269.00 and set an "overweight" rating for the company in a report on Wednesday, May 13th. Weiss Ratings cut shares of STERIS from a "hold (c+)" rating to a "hold (c)" rating in a research note on Wednesday, May 27th. Finally, UBS Group lowered their price target on shares of STERIS from $275.00 to $270.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $271.33.
Read Our Latest Stock Report on STE
About STERIS
(
Get Free Report)
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
